Millenium: The Takeda Oncology Company announced that it has submitted two supplemental NDAs (sNDAs) for Velcade (bortezomib) for Injection to the FDA. The first application is for the addition of a subcutaneous route of administration for Velcade and the second is for the use of Velcade in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

Velcade is currently approved for intravenous use only in patients with multiple myeloma and in patients with mantle cell lymphoma, a sub-type of NHL, who have received at least one prior therapy. 

For more information call (617) 551-7877 or visit